Tetravalent Dengue–Hepatitis A Co-Administration Without Serostatus Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dengue vaccines, such as Dengvaxia®, are limited by their requirement for serostatus testing, are not effective in seronegative populations, and pose increased risk in seronegative individuals, and there is a need for a vaccine that can be administered in fewer doses. Additionally, there is a need for a simultaneous vaccine against dengue and hepatitis A that can be administered without prior serostatus testing.
Innovation Solution
A method involving the simultaneous administration of a hepatitis A vaccine and a unit dose of a tetravalent dengue vaccine composition, comprising four live, attenuated dengue virus strains, on the same day, to stimulate immune responses against all dengue serotypes and hepatitis A virus, applicable to both seropositive and seronegative individuals, regardless of age or prior exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a tetravalent dengue vaccine is administered, then protection against all dengue serotypes is improved, but the risk of severe disease in seronegative individuals increases
Solution Approach 1:
The vaccine composition parameters are changed by incorporating specific adjuvants and modifying the viral antigen structure to enhance immunogenicity while reducing the risk of severe disease reactions in seronegative individuals
Solution Approach 2:
Adjuvants are introduced as intermediary substances to mediate the immune response, enhancing protection against dengue serotypes while controlling the risk of severe disease through modulated immune activation
2Reliability
If serostatus testing is required before vaccination, then vaccine safety is improved, but the complexity and time of administration increases
Solution Approach 1:
The serostatus testing step is extracted and removed from the vaccination process, allowing direct administration of the vaccine without prior testing, thereby simplifying the administration process while maintaining safety through the vaccine's modified composition
Solution Approach 2:
The vaccine is segmented into multiple serotypes within a single composition, allowing comprehensive protection without requiring separate assessments for each serotype status
3Reliability
If multiple separate vaccines are administered for dengue and hepatitis A, then comprehensive protection is improved, but the number of doses and administration time increases
Solution Approach 1:
The dengue vaccine and hepatitis A vaccine are merged into a single simultaneous administration protocol, providing comprehensive protection against both diseases in one dose, thereby reducing the total number of visits and administration time
Solution Approach 2:
The vaccination system is designed with multi-functionality to provide protection against multiple diseases (dengue and hepatitis A) through a unified administration approach, eliminating the need for separate vaccination sessions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides safe and effective protection against dengue disease and hepatitis A, reducing the risk of severe forms like DHF and DSS, and can be administered in fewer doses, suitable for individuals of various ages, including children and elderly, without prior serostatus testing.
Implementation Method 1
Due to limited replication after immunization, the attenuated virus strain does not cause disease. However, the limited viral replication is sufficient to express the full repertoire of viral antigens and can generate potent and long-lasting immune responses to the virus.
Implementation Method 2
the attenuated virus strain does not cause disease. However, the limited viral replication is sufficient to express the full repertoire of viral antigens and can generate potent and long-lasting immune responses to the virus.
Data Source
AI summary
The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.